We are live on ! Find out more
QNTM

Quantum Biopharma Class B Subordinate Voting Shares

17 hedge funds and large institutions have $2.38M invested in Quantum Biopharma Class B Subordinate Voting Shares in 2025 Q2 according to their latest regulatory filings, with 6 funds opening new positions, 3 increasing their positions, 5 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

330% more capital invested

Capital invested by funds: $553K → $2.38M (+$1.82M)

100% more first-time investments, than exits

New positions opened: 6 | Existing positions closed: 3

21% more funds holding

Funds holding: 1417 (+3)

0.18% more ownership

Funds ownership: 3.64%3.83% (+0.18%)

40% less repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 5

Holders
17
Holders Change
+3
Holders Change %
+21.43%
% of All Funds
0.22%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
6
Increased
3
Reduced
5
Closed
3
Calls
Puts
Net Calls
Net Calls Change

QNTM Hedge Fund Activity: Q2 2025 in Review

17 of the 7,598 institutional investors tracked by Wall St. Rank reported a position in Quantum Biopharma Class B Subordinate Voting Shares (QNTM) for Q2 2025, worth a combined $2.38M — up 330% from $553K a quarter earlier.

Buyers outnumbered sellers: 6 funds opened new QNTM positions and 3 closed out — a net gain of 3 holders — while 3 added to existing stakes and 5 trimmed.

The largest buyer was UBS Group, adding an estimated $546K. The largest seller was AdvisorShares Investments, cutting an estimated $148K.

  • 17 institutional investors held Quantum Biopharma Class B Subordinate Voting Shares (QNTM) as of Q2 2025, up from 14 in Q1 2025.
  • Funds reported $2.38M of Quantum Biopharma Class B Subordinate Voting Shares stock for Q2 2025, up 330% quarter-over-quarter.
  • 6 funds opened new Quantum Biopharma Class B Subordinate Voting Shares positions in Q2 2025 and 3 closed out, a net change of +3 holders.
  • The largest Quantum Biopharma Class B Subordinate Voting Shares buyer in Q2 2025 was UBS Group, an estimated $546K added.
  • The largest Quantum Biopharma Class B Subordinate Voting Shares seller in Q2 2025 was AdvisorShares Investments, an estimated $148K sold.

Based on aggregated 13F filings for Q2 2025.